Original Research

Published on 21 Oct 2022

A machine learning-based virtual screening for natural compounds capable of inhibiting the HIV-1 integrase

in Anti-Infective Agents

Lucas A. Machado
Eduardo Krempser
Ana Carolina Ramos Guimarães

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.954911

4,101 views
6 citations

Original Research

Published on 20 Oct 2022

From drugs to targets: Reverse engineering the virtual screening process on a proteomic scale

in Anti-Infective Agents

Gustavo Schottlender
Juan Manuel Prieto
Miranda Clara Palumbo
Florencia A. Castello
Federico Serral
Ezequiel J. Sosa
Adrián G. Turjanski
Marcelo A. Martì
Darío Fernández Do Porto

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.969983

3,628 views
6 citations

Review

Published on 12 Oct 2022

Chemically induced phenotypes during the blood stage development of Plasmodium falciparum as indicators of the drug mode of action

in Anti-Infective Agents

Keerthy Reghunandanan
Rajesh Chandramohanadas

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.920850

2,866 views
2 citations

Original Research

Published on 23 Sep 2022

Integrating diverse layers of omic data to identify novel drug targets in Listeria monocytogenes

in Anti-Infective Agents

Miranda Palumbo
Ezequiel Sosa
Florencia Castello
Gustavo Schottlender
Federico Serral
Adrián Turjanski
María Mercedes Palomino
Darío Fernández Do Porto

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.969415

1,954 views
6 citations

Original Research

Published on 31 Aug 2022

Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report

in Anti-Infective Agents

Chris Kahlenborn
Walter B. Severs
Khalid Nawab

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.962988

14,363 views

Brief Research Report

Published on 29 Aug 2022

Antifungal properties of (2S, 4R)-Ketoconazole sulfonamide analogs

in Anti-Infective Agents

Benjamin E. Blass
Sumant Puri
Rishabh Sharma
Brian M. Day

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.1000827

1,152 views

Review

Published on 26 Aug 2022

The challenges and opportunities for the development of COVID-19 therapeutics and preparing for the next pandemic

in Anti-Infective Agents

Emmanuel O Ogbadoyi
Ndagi Umar

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.925825

3,882 views
1 citation

Mini Review

Published on 18 Jul 2022

Nanobodies: COVID-19 and Future Perspectives

in Anti-Infective Agents

Guillermo Valenzuela-Nieto
Zaray Miranda-Chacon
Constanza Salinas-Rebolledo
Ronald Jara
Alexei Cuevas
Anne Berking
Alejandro Rojas-Fernandez

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.927164

7,994 views
10 citations

Clinical Trial

Published on 15 Jul 2022

Reszinate—A Phase 1/2 Randomized Clinical Trial of Zinc and Resveratrol Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling

in Anti-Infective Agents

Henry G. Kaplan
Kai Wang
Kimberly M. Reeves
James M. Scanlan
Christopher C. Nunn
Douglas A. Kieper
Joshua L. Mark
Inyoul Lee
Rachel Liu
Ruyun Jin

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.910124

4,520 views
1 citation

Perspective

Published on 30 May 2022

Addressing Antibiotic Failure—Beyond Genetically Encoded Antimicrobial Resistance

in Anti-Infective Agents

Evan F. Haney
Robert E. W. Hancock

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.892975

6,497 views
13 citations

Review

Published on 02 May 2022

Advances in Modelling COVID-19 in Animals

in Anti-Infective Agents

Petr Nickl
Miles Joseph Raishbrook
Linn Amanda Syding
Radislav Sedlacek

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.899587

8,900 views

Review

Published on 25 Apr 2022

Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19

in Anti-Infective Agents

Peter Buchwald

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.898035

4,446 views
8 citations

Mini Review

Published on 13 Apr 2022

COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies

in Anti-Infective Agents

Michèle Reboud-Ravaux
Chahrazade El Amri

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.892057

2,797 views
3 citations

Review

Published on 30 Mar 2022

The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19

in Anti-Infective Agents

Ana C. Puhl
Thomas R. Lane
Fabio Urbina
Sean Ekins

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.837587

6,323 views
9 citations

Review

Published on 22 Mar 2022

Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It

in Anti-Infective Agents

Michael Zhipeng Yan
Ming Yang
Ching-Lung Lai

Frontiers in Drug Discovery

doi 10.3389/fddsv.2022.858006

62,984 views
4 citations

Navigation group

Articles

A machine learning-based virtual screening for natural compounds capable of inhibiting the HIV-1 integrase

From drugs to targets: Reverse engineering the virtual screening process on a proteomic scale

Chemically induced phenotypes during the blood stage development of Plasmodium falciparum as indicators of the drug mode of action

Integrating diverse layers of omic data to identify novel drug targets in Listeria monocytogenes

Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report

Antifungal properties of (2S, 4R)-Ketoconazole sulfonamide analogs

The challenges and opportunities for the development of COVID-19 therapeutics and preparing for the next pandemic

Nanobodies: COVID-19 and Future Perspectives

Reszinate—A Phase 1/2 Randomized Clinical Trial of Zinc and Resveratrol Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling

Addressing Antibiotic Failure—Beyond Genetically Encoded Antimicrobial Resistance

Advances in Modelling COVID-19 in Animals

Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19

COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies

The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19

Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It